Christopher C. Gallen
Chief Executive Officer at Treos Bio Ltd.
Christopher C. Gallen active positions
Companies | Position | Start | End |
---|---|---|---|
Treos Bio Ltd.
Treos Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - | - |
Career history of Christopher C. Gallen
Former positions of Christopher C. Gallen
Companies | Position | Start | End |
---|---|---|---|
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2010-09-13 | 2012-02-29 |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Chief Tech/Sci/R&D Officer | 2010-01-06 | 2010-09-09 |
President | 2009-12-21 | 2010-01-06 | |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | President | 2004-06-30 | 2010-01-26 |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | President | - | 2010-01-26 |
Premier Research Worldwide /Clinical Research & Data Mgmt/ | Corporate Officer/Principal | 1998-11-30 | 1998-11-30 |
Quintiles International Clinical Research Corp. | Chief Tech/Sci/R&D Officer | 1994-12-31 | 1994-12-31 |
Wyeth Research
Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Chief Operating Officer | 2011-03-17 | - |
Chief Tech/Sci/R&D Officer | 2011-03-17 | - | |
Pharmacia, Inc. | Chief Tech/Sci/R&D Officer | - | - |
Training of Christopher C. Gallen
Emory University | Doctorate Degree |
University of Florida | Undergraduate Degree |
Statistics
International
United States | 10 |
Canada | 2 |
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 5 |
President | 3 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 5 |
Commercial Services | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 9 |
---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Health Technology |
Premier Research Worldwide /Clinical Research & Data Mgmt/ | Commercial Services |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
Wyeth Research
Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Commercial Services |
Pharmacia, Inc. | |
Quintiles International Clinical Research Corp. | |
Treos Bio Ltd.
Treos Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom. | Commercial Services |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |